SPI1 and acute lymphoblastic leukemia: Therefore, with this new study showing the high propensity for patients developing secondary malignancies that also carry the SPI1 fusion, the use of dasatinib might be considered earlier in treatment, albeit it remains to be seen whether the use of kinase inhibitors will change the trajectory of both the T‐ALL clone and the secondary malignancy.